Bayer HealthCare LLC Animal Health has announced that Baytril 100 (enrofloxacin) Injectable has three new label additions that will increase its versatility and value for swine operators.
Baytril 100 is now the only enrofloxacin approved by the Food & Drug Administration for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with Escherichia coli has been diagnosed. It also has been approved for intramuscular (IM) administration for swine and includes a dilution schedule for small pigs.
"Colibacillosis associated with E. coli is a serious threat to the swine industry," said Dr. Andrew Holtcamp, senior veterinary technical services at Bayer HealthCare Animal Health. "With these new claims, swine operators using Baytril 100 have a trusted tool that provides versatility beyond swine respiratory disease (SRD) treatment, helping to control this challenging pathogen."
According to Bayer, Baytril 100 is still the only FDA-approved enrofloxacin for treatment and control of six SRD-causing pathogens, including Mycoplasma hyopneumoniae, Bordetella bronchiseptica, Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Streptococcus suis.
In addition, Baytril 100 is the only enrofloxacin approved to fight E. coli and for IM administration in swine. Its mode of action kills disease-causing bacteria in both the resting and growth phases, making it an efficient choice for producers, Bayer said.
Baytril 100 is for use by or on the order of a licensed veterinarian. Extra-label use in food-producing animals is prohibited. Swine intended for human consumption must not be slaughtered within five days of receiving a single-injection dose. For more information about Baytril 100, or to obtain a product label, call Bayer Veterinary Services at +1 (800) 422-9874 or visit www.BayerLivestock.com.